Eric Halioua, President & CEO of PDC*line Pharma will be chairman at a roundtable session on “Next generation therapeutic vaccines : viral, bacterial and cell based” at World Immunotherapy Congress in...
Eric Halioua, President & CEO of PDC*line Pharma will present the company at the Sachs Associate 17th Annual Biotech in Europe Forum in Basel Wednesday September 27th.
Eric Halioua, CEO of PDC*line Pharma will be speaker at an official satellite workshop at BIO US (San Diego, CA – US) to present the company strategy for new immunotherapies. The workshop entitled “Wi...
We are very pleased to inform you that the 8th edition of MATWIN’s international board has awarded PDC*line Pharma with the prize of most promising project in the “start-up” category.
This prize...
Three Belgian investment funds and several specialized international business angels have participated in this round, which will allow the company’s cancer immunotherapy technology to reach the...
PDC*line Pharma will attend BIO-Europe in Cologne (Germany)
November 7–9, 2016
Cologne, Germany
Let’s meet there !
PDC*line Pharma presents at the Sachs 16th Annual Biotech in Europe forum
PDC*line Pharma receives Advanced-Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for its new class of therapeutic cancer vaccines (PDC*vac)
June 15th 2015 –...
From right to left: Isabelle Tabah-Fisch (CMO), Laurent Levy (CEO) and Joel Plumas...
PDC*line Pharma received €500 k in grants and won 3 awards in 2014: the Worldwide Innovation Challenge 2030, the i-Lab French competition, and the French plan “medical biotechs”.
